Molecular Markers in Treatment in Endometrial Cancer (MoMaTEC)

University of Bergen

Status: Unknown

Conditions: Neoplasm Metastasis; Endometrial Neoplasms

Treatments: Procedure: Tumor biopsy study

Study type: Observational

Funder types: Other

Identifiers

NCT00598845

REK 96/1478-2

NSD 15501

Helse Vest 911351

Details and patient eligibility

About

The purpose of this prospective multicenter trial is to investigate the value of molecular markers in endometrial cancer for predicting lymph node metastasis and prognosis in relation to treatment.

Full description

This is a prospective multicenter study to investigate the predictive value of molecular markers in endometrial cancer for lymph node metastasis, prognosis and treatment. For the previously studied tumor markers p53, p16, ER, PR and HER2neu, we want to investigate the expression in curettage material in relation to lymph node metastasis and prognosis among endometrial carcinoma patients. We also want to investigate the distribution of genetic alterations in fresh frozen tumor tissue in order to design prospective randomized treatment trials of metastatic endometrial cancer based on molecular profile. There will be a special emphasis on disturbances in the pathways influenced by new targeted therapy, such as inhibitors of Her2/NEU, EGFR, receptor tyrosine kinase, mTOR, PTEN and hormone receptor pathways.

Enrollment: 1,000 estimated patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women with endometrial carcinoma
• Available endometrial biopsy
• Informed consent

Exclusion criteria

• No informed consent

Trial design

1,000 participants in 1 patient group

Consecutive numbers

Description:

Patients with endometrial cancer

Treatment:

Procedure: Tumor biopsy study